YOLT-202
Phase 1Small molecule
YOLT-202 is one of 9 small molecule programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Alpha-1 Antitrypsin Deficiency
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
SAR447537
SanofiPhase 2
Duragesic
CCephalon
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ativan
BBausch Health Americas, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
YOLT-202
RRenJi Hospital
Phase 1
Oxycodone/acetaminophen
MMontefiore Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-202. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRenJi Hospital